The Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8 company and a Schedule B public sector enterprise, established by the Department of Biotechnology under the Ministry of Science and Technology, Government of India. It positions itself as an interface agency linking industry and academia, with the aim of strengthening emerging biotech enterprises and helping them develop products the country needs. Its office is located on the fifth floor of NSIC Business Park, NSIC Bhawan, Okhla Industrial Estate, New Delhi 110020.
BIRAC provides funding but does not operate its own laboratory or incubator. Its grant schemes pay a company, an LLP or an academic institution to carry out a piece of work. Under its incubation scheme, BioNEST, it pays other organisations to build and run bio-incubators, and those incubators are the ones equipped with benches, instruments and a front desk. Its equity schemes, the SEED Fund and LEAP Fund, are deployed by selected BioNEST incubators acting as BIRAC's fund partners, so a startup accesses that money through an incubator rather than by applying to BIRAC directly. The Fund of Funds, AcE, operates at one further remove: BIRAC invests in SEBI-registered Category I and II Alternative Investment Funds, and those daughter funds in turn invest in startups.
Its schemes span healthcare, life sciences, diagnostics, medical devices, drugs and drug delivery, vaccines, biosimilars and stem cells, industrial biotechnology including secondary agriculture, agriculture, bioinformatics, waste management, sanitation and clean energy. The BIG grant sorts proposals into seven categories along these lines and encourages proposals that combine biotech with engineering, artificial intelligence, sensors, automation and robotics. BIG explicitly does not fund basic or exploratory research, projects with little novelty, projects lacking a real biotech component, or late-stage clinical or field-trial work, and the grant cannot pay for a PhD. Applicant requirements differ sharply by scheme: BIG is for an Indian company or LLP incorporated no more than five years before the call opens, at least 51 per cent beneficially owned by resident Indian citizens, with its own working in-house R&D lab or a place at an incubator, led by a Project Leader who is a shareholder holding an undergraduate degree, and a startup may receive BIG support only once. SBIRI and BIPP, under the i4 umbrella, are for Indian companies and LLPs, alone or in a consortium, with or without an academic partner, subject to the same 51 per cent Indian-ownership test and to adequate in-house facilities verified on a site visit or a place at a recognised incubation facility. PACE is the academic route, with a public or private institute, university, NGO or research foundation as primary applicant, registered or accredited by a government body, and an industry or LLP partner optional under its Academic Innovation Research component and compulsory under its Contract Research Scheme. SITARE and E-YUVA serve students: SITARE's award grant is for Indian students doing a PhD or a Master's, its appreciation grant for undergraduates who attend a Biotech Innovation Ignition School, with a stated preference for students from Tier II and Tier III cities and aspirational districts; E-YUVA runs two fellow categories, one for postgraduates and above and one for undergraduates, hosted at E-YUVA Centres inside universities and institutes.
BioNEST is how BIRAC reaches founders who need space rather than a cheque. Its page lists 73 supported bio-incubators with a cumulative area of 1,102,430 sq ft, hosted by institutions such as C-CAMP, IKP Knowledge Park, SINE at IIT Bombay, IIT Kanpur, AIIMS Delhi, Bangalore Bioinnovation Centre, KIIT-TBI, the Regional Centre for Biotechnology and several NIPER campuses; BIRAC's homepage gives a different pair of figures for the same thing, 94 centres and 1,034,470 sq ft, without explaining the gap. Each E-YUVA Centre carries its own pre-incubation space of 3,000 sq ft or more and is mentored by a BioNEST incubator. Beyond funding, BIRAC runs an in-house IP and Technology Management cell that conducts patentability, freedom-to-operate, validity and prior-art searches, assists with patent drafting, filing and prosecution, carries out patent and technology landscaping, and handles technology evaluation, marketing and licence negotiation; it runs a patent assistance scheme and has empanelled outside IP and technology-transfer firms. A separate Regulatory Affairs and Policy Advocacy department helps startups and SMEs navigate regulation, and grantees receive continuing mentoring from BIRAC and their BIG Partner on technical advice, IP, legal matters, trainings, regulatory advice, business mentoring and investor connects.
BIRAC's published counts include more than 900 products and technologies supported, more than 1,350 pieces of intellectual property generated, more than 35,000 jobs created, more than 400 academic institutes supported, more than 28,000 proposals assessed and a mentor pool of more than 10,000. Its headline beneficiary count is unusable as published, since the same block of figures gives both 1,500,000 and 5,000-plus for what reads as the same population, so that number is omitted here. Its equity schemes report 159 startups backed as of February 2023, and its Fund of Funds reports 16 daughter funds and more than 102 biotech startups as of August 2025. The board is chaired by Dr Rajesh S. Gokhale, Secretary of the Department of Biotechnology; Dr Dhananjay K. Tiwary, Senior Adviser and Scientist-H at DBT, is Managing Director; FCA Nidhi Shrivastava is Director, Finance; Ms Ekta Vishnoi, Joint Secretary (Administration) at DBT, is the government nominee director; and Dr Mriganka Talukdar is a non-official independent director. BIRAC set up its first Regional Innovation Centre at IKP Knowledge Park in Hyderabad, and vacancies and tenders are published on its own site. Applications follow a single route: register as an organisation or a user on the BIRAC website, log in, select the scheme, submit a new proposal and finally submit it, which is possible only while a call is open. Scheme-by-scheme proformas are published on BIRAC's proposal submission page. Calls, rather than paperwork, are the constraint: when checked on 23 September 2026, the Current Calls table on BIRAC's Call for Proposal page was empty, the E-YUVA page stated there were no active calls, and the Product Commercialization Program Fund page stated its call was closed until further notice.